Tag: Trastuzumab

Blood clots are a reported serious side effect associated with Herceptin (trastuzumab), though the link is often complex and influenced by other factors inherent to cancer and its treatment. While Herceptin's main side effects typically involve the heart and lungs, patients should be aware of the signs and risks of blood clots during therapy.

The global monoclonal antibody therapeutics market was valued at over USD 233 billion in 2024 and is projected to grow significantly [1.11.1]. This highlights the pivotal role of these engineered proteins in modern medicine. So, **what is an example of a monoclonal antibody being used?**

Approximately 15-20% of invasive breast carcinomas overexpress the HER2 protein, a key target for specific cancer therapies [1.4.7]. For these cancers, a common question is, 'What's another name for trastuzumab?' The most widely known is the original brand name, Herceptin [1.2.2].

Approved in 2018 as a biosimilar to Herceptin, HERZUMA is a targeted therapy used to treat HER2-overexpressing cancers. Understanding how is HERZUMA administered is crucial for patients, as the intravenous infusion process involves specific protocols regarding administration timing and patient monitoring. The administration is a multi-step process performed by trained healthcare professionals in a controlled setting.